AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Gilead Sciences Stock Drops 42.46% in Trading Volume, Ranks 172nd Despite Positive Trodelvy Trial Results
Generated by AI AgentAinvest Volume Radar
Wednesday, May 28, 2025 8:01 pm ET1min read
On May 28, 2025,
(GILD) experienced a significant decline, with its trading volume dropping by 42.46% to 4.97 billion, ranking 172nd in the day's market activity. The stock price decreased by 0.60%.Gilead Sciences announced that its antibody-drug conjugate, Trodelvy, achieved the primary endpoint in a Phase 3 trial, demonstrating superior efficacy compared to chemotherapy in treating breast cancer. This positive outcome reinforces Trodelvy's potential as a backbone therapy for metastatic triple-negative breast cancer (TNBC).
The Phase 3 ASCENT-03 study, which evaluated Trodelvy in patients with first-line metastatic TNBC, showed significant improvements in progression-free survival (PFS). These results are crucial as they validate Trodelvy's effectiveness in a challenging patient population, potentially expanding its therapeutic applications.
Gilead's positive data on Trodelvy in first-line breast cancer treatment has garnered attention, highlighting the company's ongoing efforts in oncology research. The successful trial outcomes are expected to bolster investor confidence in Gilead's pipeline and its ability to deliver innovative cancer therapies.
Ainvest Volume Radar
Hunt down the stocks with explosive trading volume.
Latest Articles
Aptiv Slides 1.39% as Institutional Sells Clash with Strong Q3 Earnings and NYSE Volume Ranks 497th
Dec.22 2025
Diamondback Energy Gains 0.22% Despite 489th Volume Rank as Earnings Outperformance and Strategic Asset Sales Bolster Investor Confidence
Dec.22 2025
Kinross Gold's 2.66% Surge Despite 45.31% Volume Drop, 452nd in Market Activity Rank
Dec.22 2025
ATI Shares Rise 2.19% Despite 46% Volume Drop, Ranks 478th in Trading Activity
Dec.22 2025
United Therapeutics Shares Drop 0.65% Amid Insider and Institutional Selling, Trading Volume Ranks 465th
Dec.22 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet